Pfizer Inc. announce that the coronavirus vaccine that is has developed with German partner, BioNTech , has a 95% efficacy rate, in its complete results from a late-stage trial. The result is an improvement from the interim results of efficacy rate of 90% last month, which was based a cohort of around 94 patients.
The latest result is consistent across all age and race demographics and based on a total case cohort of 170, according to Pfizer.
A few days ago, Moderna published a efficacy rated of 94.5% of its vaccine, based on early look of its late-stage trial.
Pfzer and BioNTech said they the will apply for Emergency Use Authorization from the U.S. Food & Drug Administration in the coming days. They will produce 50 million does by the end of this year, and 1.3 billion doses by next year.